Elevance Health Inc. (NYSE:ELV)

Overall, the cash flow statement reveals a complex pattern of cash generation and usage over the five-year period. While operating activities consistently provide a substantial cash inflow, this is frequently offset by significant cash outflows from investing and financing activities. A notable shift occurs in the later years, with increased reliance on financing and a decline in operating cash flow.

Operating Activities

Net cash provided by operating activities demonstrates a generally decreasing trend, starting at US$8,364 million in 2021 and declining to US$4,290 million in 2025. While remaining positive throughout the period, the rate of decline accelerates in the later years. Adjustments to reconcile net income to net cash provided by operating activities fluctuate, initially increasing from US$2,269 million in 2021 to US$2,380 million in 2022, then decreasing significantly to negative US$163 million in 2024 and further to negative US$1,371 million in 2025. This suggests increasing non-cash charges or changes in working capital negatively impacting cash flow. Significant fluctuations are observed in changes in operating assets and liabilities, moving from a positive US$1,193 million in 2021 to a negative US$3,277 million in 2025, indicating a growing strain on working capital management.

Investing Activities

Investing activities consistently represent a significant cash outflow. Purchases of investments are substantial, ranging from approximately US$16 billion to US$25 billion annually. Proceeds from the sale of investments partially offset these outflows, but do not fully compensate for them. Purchases of subsidiaries also contribute to the cash outflow, with a particularly large outflow in 2024. Purchases of property and equipment remain relatively stable, around US$1.1 to US$1.3 billion per year. Overall, net cash used in investing activities decreases from US$9,638 million in 2021 to US$1,344 million in 2025, primarily due to a reduction in purchases of investments.

Financing Activities

Financing activities exhibit considerable volatility. In 2021 and 2022, net cash provided by financing activities is positive, driven by proceeds from long-term and short-term borrowings. However, 2023 sees a substantial net cash outflow of US$3,349 million, largely due to repayments of debt and repurchase of common stock. 2024 shows a return to positive cash flow from financing, but 2025 experiences another significant outflow. Repurchase and retirement of common stock and cash dividends consistently represent substantial cash outflows, totaling approximately US$3.0 to US$3.5 billion annually. The company’s reliance on debt financing fluctuates, with significant issuance in some years and substantial repayments in others.

Key Trends & Observations

A notable trend is the increasing reliance on financing activities to cover cash needs, particularly in the later years. While operating cash flow remains positive, its decline, coupled with substantial investing outflows, necessitates increased borrowing and equity transactions. The fluctuations in policy liabilities and accounts payable suggest potential shifts in the company’s insurance and payment practices. The significant changes in deferred income taxes also warrant further investigation. The impact of foreign exchange rates on cash is relatively minor throughout the period.

In conclusion, the cash flow statement indicates a company actively managing its investments and capital structure. However, the declining operating cash flow and increasing reliance on financing activities suggest potential challenges in maintaining long-term financial stability without improvements in operational efficiency or a shift in investment strategy.